Even with this partial rebound, Lilly's share price remains roughly 13% below the peak set in late August. Some investors ...

Conditions are getting a bit more challenging for the drugmaker.

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook ...

But another titan has started to inflate. Ladies and gentlemen, let’s talk about Eli Lilly. There’s something curious about the chart below. Nvidia, the poster child of the AI revolution ...

Those who follow my work closely know that I have been a big fan of pharmaceutical firm Eli Lilly and Company (NYSE:LLY) for a little while now. My first article about the company, published in ...

Wall Street Bulls Berenberg: Out of the gate, Berenberg analyst Kerry Holford lifted the firm's price target on Eli Lilly stock by 17.6% to $1,000 from $850 and maintained a buy rating. The new ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing back ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...